Non-Small Cell Lung Cancer Therapeutics Market in Major Developed Markets to 2021

1
Non-Small Cell Lung Cancer Therapeutics in Major
Developed Markets to 2021 - Emergence of
Immunotherapies Drives Market Growth and Creates
A Competitive Second-Line
2
Report Description
Non-Small Cell Lung Cancer Therapeutics in Major
Developed Markets to 2021 - Emergence of
Immunotherapies Drives Market Growth and Creates
A Competitive Second-Line Summary Non-Small Cell
Lung Cancer (NSCLC) is the second most common
cancer globally, and the most common cause of
cancer-related mortality. Such a poor outlook,
particularly for patients with advanced disease,
has created a pressing need for improved
therapeutic options. The NSCLC market is
undergoing a gradual change from a focus on
generic chemotherapy regimens to complex
treatment landscape based on different NSCLC
subtypes and the presence of various molecular
aberrations. In the current market, patients with
non-squamous histology can be treated with more
efficacious therapies such as Alimta
(pemetrexed), while patients harboring activating
mutations in EGFR or ALK can be prescribed
targeted therapy. While the NSCLC developmental
pipeline must aim to improve the outlook for all
patients, there is currently a lack of options
for patients with squamous cell histology or
other detectable molecular characteristics
besides EFGR and ALK mutations. Get complete
Report _at_ http//www.bigmarketresearch.com/non-smal
l-cell-lung-cancer-therapeutics-in-major-developed
-to-2021-emergence-of-immunotherapies-drives-growt
h-and-creates-a-competitive-second-line-market
3
Report Description
Scope The NSCLC market will be valued at 10.9
billion in 2021, growing from 6.1 billion in
2014 at a CAGR of 8.5 - - How will
immunotherapies such as Keytruda affect growth?
- What effect will patent expirations of Tarceva
and Alimta have on market value? The NSCLC
pipeline is large and diverse, with an increased
presence of mAbs and specific targeted therapies
in contrast to the market - - What are the
common targets and mechanisms of action of
pipeline therapies? - Will the pipeline address
unmet needs such as a lack of treatments for
squamous cell patients? - What implications
will the increased focus on targeted therapies
have on the future of NSCLC treatment? Enquire
about this report _at_ http//www.bigmarketresearch.c
om/report-enquiry/332536
4
Report Description
Numerous late-stage pipeline therapies with a
strong clinical record have the potential to
enter the market over the forecast period - -
How have promising late-stage therapies performed
in clinical trials? - How would the approval of
Rociletinib affect the competitive landscape? -
What is the individual commercial forecast for
each therapy? The market forecasts indicate that
the US contributes the most to global market
value due to a large treatment population and the
high price of premium therapies. - How will
ACoT and market size vary between the eight major
markets? - How could a change in risk factors
such as population age or smoking habits
influence the market? Licensing deals are the
most common form of strategic alliance in NSCLC,
with total deal values ranging from under 10m to
over 1 billion. - How do deal frequency and
value compare between target families and
molecule types? - What were the terms and
conditions of key licensing deals?
5
Report Description
Reasons to buy This report will allow you to -
- Understand the current clinical and commercial
landscape by considering disease pathogenesis,
diagnosis, prognosis, and the treatment options
available at each stage of diagnosis, including a
clinical comparison of marketed therapies. -
Visualize the composition of the NSCLC market in
terms of dominant therapies for each patient
subset along with their clinical and commercial
standing. Unmet needs in the current market are
highlighted to allow a competitive understanding
of gaps in the current market. - Analyze the
NSCLC pipeline and stratify pipeline therapies by
stage of development, molecule type and
molecular target. - Understand the potential of
late-stage therapies with extensive profiles of
products that could enter the market over the
forecast, highlighting clinical performance,
potential commercial positioning, and how they
will compete with other therapies. - Predict
NSCLC market growth in eight major markets with
epidemiological and ACoT forecasts across the US,
Canada, UK, France, Germany, Italy, Spain and
Japan, as well as individual drug contributions
to market growth. - Identify commercial
opportunities in the NSCLC deals landscape by
analyzing trends in licensing and co-development
deals.
6
Table of Contents
1 Table of Contents 2 Introduction 3 Marketed
Products 4 NSCLC Pipeline 5 Market Forecast 6
Strategic Consolidations 7 Appendix Get Complete
TOC _at_ http//www.bigmarketresearch.com/non-small-c
ell-lung-cancer-therapeutics-in-major-developed-to
-2021-emergence-of-immunotherapies-drives-growth-a
nd-creates-a-competitive-second-line-market
7
FOR MORE DETAILS
Visit us at
http//www.bigmarketresearch.com/non-small-cell-lu
ng-cancer-therapeutics-in-major-developed-to-2021-
emergence-of-immunotherapies-drives-growth-and-cre
ates-a-competitive-second-line-market
Stay With Us
TELEPHONE [phone] EMAIL
help_at_bigmarketresearch.com
5933 NE Win Sivers Drive,205, Portland, OR
97220United States